Clinical Trial Update: Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluated the safety and efficacy of the fixed-dose combination dolutegravir/lamivudine (DTG/3TC) in therapy-naive HIV-1-infected adolescents, w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Dovato (dolutegravir/lamivudine)

Snippet

Sponsor: ViiV Healthcare | Conditions: HIV Infections | Phase 3 | Status: COMPLETED | Results posted: 2022-08-08